• Donate
  • About Us
    • Marking 25 Years of Action Duchenne
    • Our Purpose
    • What We Do
    • Our Impact
    • Our Team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
    • Recently diagnosed
    • Children and Young People
    • Schools
    • End of Life and Bereavement
  • Community Summit
    • Action Duchenne Community Summit 2026
    • Community Summit 2026 Agenda and Sponsors
    • Highlights from the Action Duchenne Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
    • Friends of Action Duchenne
    • COMMUNITY BUSINESS PARTNERS: Creating Lasting Impact for Families Living with Duchenne
    • Side by Side: Running Together for Action Duchenne – Your Invitation
    • Upcoming Events and Challenges
    • Give in memory and help us support every family, every time.
    • You Do YOU – Fundraise Your Way
    • Fundraising at school
    • Donate by cheque and post
    • Welcome to our Runner Hub
  •  0 items - £0.00
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to secondary navigation
  • Skip to primary sidebar
  • Skip to footer

Before Header

  • My account
  •  0 items - £0.00

Action Duchenne

Header Right

  • Donate
  • About Us
    • Marking 25 Years of Action Duchenne
    • Our Purpose
    • What We Do
    • Our Impact
    • Our Team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
    • Recently diagnosed
    • Children and Young People
    • Schools
    • End of Life and Bereavement
  • Community Summit
    • Action Duchenne Community Summit 2026
    • Community Summit 2026 Agenda and Sponsors
    • Highlights from the Action Duchenne Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
    • Friends of Action Duchenne
    • COMMUNITY BUSINESS PARTNERS: Creating Lasting Impact for Families Living with Duchenne
    • Side by Side: Running Together for Action Duchenne – Your Invitation
    • Upcoming Events and Challenges
    • Give in memory and help us support every family, every time.
    • You Do YOU – Fundraise Your Way
    • Fundraising at school
    • Donate by cheque and post
    • Welcome to our Runner Hub

Wave Life Science Announce Positive Data from FORWARD-53 Clinical Trial

You are here: Home / News / Exon skipping news / Wave Life Science Announce Positive Data from FORWARD-53 Clinical Trial

26 March 2025 by John Marrin

Wave Life Sciences announced today positive data following 48 weeks of dosing in the FORWARD-53 clinical trial evaluating the investigational molecule WVE-N531 in boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.  This 48-week data set represents biopsy data for eight of the eleven boys (all ambulatory) who received a 10 mg/kg dosing of WVE-N531 every other week.

Key Results

  • WVE-N531 was safe and well tolerated through 48 weeks of dosing.  
  • WVE-N531 led to 54% mean exon skipping through 48 weeks of dosing.  
  • WVE-N531 showed dystrophin expression stabilised between 24 and 48 weeks of dosing, with a mean (average) of 7.8% muscle content-adjusted dystrophin; 88% of boys achieved greater than 5% average dystrophin between 24 and 48 weeks.  

Participants showed significant improvements in multiple indicators of muscle health through 48 weeks, indicating a shift towards healthy muscle. These data include: 

  • A statistically significant decline in the amount of muscle fibrosis (scarring) between 24 and 48 weeks.  
  • Decreases in markers of inflammation  
  • A 50% decrease in blood creatine kinase (CK), a biomarker for muscle damage, which occurred on top of a stable corticosteroid regimen.  
  • Improved organisation and uniformity of muscle fibres in muscle tissue. 

The data also showed benefits in multiple functional assessments, including:  

  • Time-to-Rise (TTR) showed a statistically significant and clinically meaningful 3.8-second difference favouring WVE-N531 compared with natural history. This is the largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks.  
  • North Star Ambulatory Assessment (NSAA) showed positive trends favouring WVE-N531 relative to natural history (1.2-point improvement; not statistically significant).

Next Steps

All 11 boys in FORWARD-53 have advanced to the extension portion of the study, now receiving monthly doses of WVE-N531.

Wave Life Sciences intends to file a New Drug Application (NDA) in 2026 for accelerated approval of WVE-N531. The NDA filing will be based on all FORWARD-53 data, which will include additional data to support monthly dosing. Furthermore, the company is planning for the global confirmatory trial of WVE-N531, advancing their near-term clinical programs for exons 52, 51, 45 and 44, and expect to submit multiple Clinical Trial Applications (CTAs) for other exon skipping programs in 2026.

Read more

FORWARD-53

This is a Phase 1b/2 open-label study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in patients with Duchenne muscular dystrophy (DMD) who have a documented mutation of the DMD gene that is amenable to exon 53 skipping intervention. This study has 2 parts, Part A and Part B. Both Part A and Part B are now completed. Following completion of Part B, all patients have elected to continue to receive study treatment in an optional open-label extension arm.

WVE-N531

WVE-N531 is an exon skipping oligonucleotide being developed as a disease modifying treatment for boys with Duchenne muscular dystrophy amenable to exon 53 skipping. WVE-N531 was designed using Wave’s best-in-class oligonucleotide chemistry modifications, including PN backbone chemistry. WVE-N531 has received Orphan Drug Designation and Rare Paediatric Disease Designation from the U.S. Food & Drug Administration.

If you have any questions or queries regarding the information presented in this article, please reach out to us at info@actionduchenne.org

Share this:

Category: Exon skipping news

Previous Post: « Dyne Therapeutics Announce New Long Terms Clinical Data from DELIVER Trial of DYNE 251
Next Post: Family Science Education Day »

Primary Sidebar

From our community

From receiving support to giving it back: Nicola’s journey with Action Duchenne

Written by Nicola Culverhouse “If you had told me two years ago that I would be volunteering for Action Duchenne, I wouldn’t have believed you. Our four-year-old son, Kitto, was diagnosed with Duchenne in August 2024, following 12 months of infections and investigations. He had met all his milestones and we had absolutely no concerns …

Action Duchenne Residential Weekends: “Adventure is still possible”

Action Duchenne Residential Weekends: “Adventure is still possible“ With a Duchenne diagnosis, it often feels that there is an ever-growing list of things that become more difficult. The freedom to choose to take part in activities, to continue hobbies or even just to pop round to a friend’s house changes into something that needs planning, …

Honouring George and Finding Community

Honouring George and Finding Community Remembering George one year on. “If I’d never experienced George having Duchenne, I wouldn’t be half the person I am now. He taught me so much about life. I truly believe that boys with Duchenne are just the most awesome people in the world.”  On Sunday 26th April 2026, Louise Ruddick ran the …

Footer

Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA

0300 102 1762
info@actionduchenne.org 

 

 

 

 

 

 

 

 

Subscribe to our mailing list

Do you consent to receiving regular email updates? *
Email Format
  • Accessibility
  • Privacy Policy
  • Terms & Conditions

Site Footer

Fundraising Regulator badge with validation link

© Action Duchenne - Registered Charity No 1101971 - Scottish Charity No SC043852